Fennec Pharmaceuticals Reports Positive Results for PEDMARK® in Japan

The latest announcement is out from Fennec Pharmaceuticals ( (TSE:FRX) ).

Fennec Pharmaceuticals announced positive results from a Phase 2/3 clinical trial in Japan, demonstrating that PEDMARK® significantly reduces cisplatin-induced hearing loss in pediatric and adolescent patients without affecting the drug’s antitumor efficacy. With a high tumor response rate and no adverse interactions observed, the company plans to pursue registration in Japan and explore partnering opportunities, potentially enhancing its market presence and offering a solution to a significant unmet medical need.

The most recent analyst rating on (TSE:FRX) stock is a Buy with a C$13.00 price target. To see the full list of analyst forecasts on Fennec Pharmaceuticals stock, see the TSE:FRX Stock Forecast page.

Spark’s Take on TSE:FRX Stock

According to Spark, TipRanks’ AI Analyst, TSE:FRX is a Neutral.

Fennec Pharmaceuticals shows strong revenue growth and improved cash flow, key for its industry. However, profitability issues and a weak balance sheet weigh down the score. Technical indicators and valuation reflect mixed signals, while positive earnings call sentiments provide some optimism. Addressing financial challenges will be crucial for future performance.

To see Spark’s full report on TSE:FRX stock, click here.

More about Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing therapies to protect against chemotherapy-induced hearing loss. Their primary product, PEDMARK®, is the first and only FDA-approved therapy aimed at reducing ototoxicity in pediatric patients undergoing cisplatin treatment for localized, non-metastatic solid tumors.

Average Trading Volume: 1,258

Technical Sentiment Signal: Buy

Current Market Cap: C$381.3M

See more data about FRX stock on TipRanks’ Stock Analysis page.